This article provides a comprehensive overview of the risks associated with the administration of chemotherapy, monoclonal antibodies and targeted or biological therapies in the management of solid tumours. The main physiological actions of these agents are discussed, with reference to the immediate infusion-related side effects and complications that may arise from an extravasation injury. The article focuses on the identification and early recognition of these risk factors to implement preventive measures and appropriate management strategies.
Nursing Standard. 30, 25, 51-60. doi: 10.7748/ns.30.25.51.s48Correspondence
All articles are subject to external double-blind peer review and checked for plagiarism using automated software.
Received: 29 May 2015
Accepted: 07 October 2015
Alternatively, you can purchase access to this article for the next seven days. Buy now